Devan V. Mehrotra
Merck & Co., Inc., Rahway, NJ, USA (United States) · 152 works · 6,455 citations · h-index 39
Top works
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
- HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis
- Minimum risk weights for comparing treatments in stratified binomial trials
- Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade B gag/pol/nef Vaccine in Healthy Adults
- Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team
- Use of the false discovery rate for evaluating clinical safety data
- Scientific white paper on concentration-QTc modeling
- Virological and Immunological Effects of Combination Antiretroviral Therapy with Zidovudine, Lamivudine, and Indinavir during Primary Human Immunodeficiency Virus Type 1 Infection
- Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials?
- Detection of HIV Vaccine-Induced Cell-Mediated Immunity in HIV-Seronegative Clinical Trial Participants Using an Optimized and Validated Enzyme-Linked Immunospot Assay
- A Cautionary Note on Exact Unconditional Inference for a Difference between Two Independent Binomial Proportions
- Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials
- Enhanced Rates and Magnitude of Immune Responses Detected against an HIV Vaccine: Effect of Using an Optimized Process for Isolating PBMC
- Analysis of incomplete longitudinal binary data using multiple imputation
- Evaluation of Cellular Immune Responses in Subjects Chronically Infected with HIV Type 1
- Statistical Considerations for NonInferiority/Equivalence Trials in Vaccine Development
- Estimating the Benefit of an HIV‐1 Vaccine That Reduces Viral Load Set Point
- A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated
- A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development
- AIDS Clinical Trials Group 5197: A Placebo‐Controlled Trial of Immunization of HIV‐1–Infected Persons with a Replication‐Deficient Adenovirus Type 5 Vaccine Expressing the HIV‐1 Core Protein